Log in
Enquire now
‌

US Patent 9782407 Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors

Patent 9782407 was granted and assigned to Dr. Reddy's Laboratories on October, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
0
Current Assignee
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
97824070
Patent Inventor Names
Sivaram Pillarisetti0
Jennepalli Sreenu0
Santanu Maitra0
Shanavas Alikunju0
Anima Baruah0
Christopher W. Alexander0
Dibyendu De0
Indu Dager0
...
Date of Patent
October 10, 2017
0
Patent Application Number
146874670
Date Filed
April 15, 2015
0
Patent Primary Examiner
‌
Susanna Moore
0
Patent abstract

The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9782407 Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.